Nuclear Medicine Market Surpass $16.2 Billion By 2026 | CAGR 9.5%

Author: Acumen Research and Consulting

Acumen Research and Consulting has published a new report titled "Nuclear Medicine Market (By Product: Diagnostics [SPECT {TC-99m, TL-201, GA-67, I-123, Others}, PET {F-18, RB-82, Others}], Therapeutics [Alpha Emitters {RA-223, Others}, Beta Emitters {I-131, Y-90, SM-153, Re-186, Lu-117, Others}, Brachytherapy {Cesium-131, Iodine-125, Palladium-103, Iridium-192, Others}]; By Application: Diagnostics [Cardiology, Neurology, Oncology, Thyroid, Lymphoma, Others], Therapeutics [Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumor, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026". The global nuclear medicine market size is anticipated to expand around USD 16.2 billion by 2026, this market is anticipated to grow with 9.5% CAGR during the forecast time period.

Requirement for ahead of schedule and precise analytic strategies, combined with developing need for better treatments, is driving the market. Expanding occurrence of disease and cardiovascular issue is likewise contributing toward market development as nuclear medicine has demonstrated fairly precise in the determination and treatment of such conditions.

Download Report Sample Pages For Better Understanding@ 

As per the World Health Organization (WHO) in February 2015, the quantity of new instances of Cancer is required to develop by around 70% throughout the following two decades. All around, 8.8 million individuals died from cancer growth in 2015. Cancer represents one out of each six deaths all around.

Expanding predominance of cardiovascular diseases is filling market development. These illnesses represented more than 17.7 million deaths in 2015 internationally. The number is foreseen to cross around 23 million by 2030. An expected 31.0% of worldwide death can be ascribed to cardiovascular diseases.

Currently, radio pharmaceuticals are generally utilized in the field of oncology and cardiovascular diseases. Continuous research and studies exhibiting positive outcomes is extending the extent of radioisotope applications for analysis and treatment of bone ailments, respiratory illnesses, thyroid-related ailments, and states of the stomach related tract. Alongside these applications, radioisotopes are to a great extent utilized in radio pharmacology to think about drug movement in lab subjects.

The global nuclear medicine market is segmented into product, application,and region.On the basis of product, the global nuclear medicine market is segmented into diagnostics (SPET (TC-99m, TL-201, GA-67, I-123, and Others), PECT(F-18, RB-82, and Others)) and therapeutics (Alpha Emitters (RA-223, Others), Beta Emitters (I-131, Y-90, SM-153, Re-186, Lu-117, Others), Brachytherapy(Cesium-131, Iodine-125, Palladium-103, Iridium-192, and Others)). On the basis of application, the global nuclear medicine market is segmented into diagnostics and therapeutics. Diagnostics is further bifurcated into cardiology, neurology, oncology, thyroid, lymphoma, and others. Therapeutics is further bifurcated into thyroid, bone metastasis, lymphoma, endocrine tumor, and others.On the basis of region the global Nuclear medicine market is bifurcated into Europe, Latin America, North America, Middle East & Africa, and Asia Pacific.

By application, the radio pharmaceuticals market is bifurcated into diagnostics and therapeutics. Diagnostic applications comprise of cardiology, nervous system science, oncology, thyroid, and lymphoma; oncology is the biggest portion by demonstrative application, while cardiology is required to enlist solid development over the forthcoming years.


Prominent therapeutic applications comprise of thyroid, bone metastasis, lymphoma, and endocrine tumor. While bone metastasis forms the biggest portion by therapeutic applications, the thyroid section is slated to be exceedingly worthwhile over the coming years.

Nuclear medicine diagnostic techniques give better understanding of adisease contrasted with customarily utilized demonstrative strategies, for example, including x-ray, ultrasound, CT, and MRI. High picture lucidity empowers doctors to precisely choose the course of medicines, limiting inconveniences in experimentation medications.

North America initiated the market in 2018, representing an offer of over 44.0% that year. This can be ascribed to progressive healthcare infrastructure in the district, particularly in U.S. Increasing burden of disease and different cardiovascular disarranges is likewise a high effect rendering factor driving the market.

Asia Pacific is foreseen to enroll the most astounding CAGR of 10.9% during the forecast period. Demand for nuclear medicine is expanding in developing markets, for example, China and India because of rising disposable income, enhancing medicinal healthcare standards, and favourable reforms in foreign policies. China is overwhelms the Asia Pacific market and is probably going to clutch its lead position through 2026.

Market companies are concentrating on implementing new strategies for instance regional expansion, partnerships, mergers and acquisitions, new product launches, and distribution agreements to surge their revenue share. And also, growing R&D investments paired with technical advancements to commercialize highly efficient products are expected to offer huge growth opportunities for industry participants. Some of the main businesses present in the nuclear medicine market are Eczacibasi-Monrol, Eckert & Ziegler Group, NTP Radioisotopes SOC Ltd.,Mallinckrodt Pharmaceuticals,Australian Nuclear Science & Technology Organization (ANSTO),GE Healthcare,Nordion, Inc.,Jubilant Life Sciences,The Institute of Radio elements,and Bracco Imaging S.p.A. Significant strategic initiatives undertaken by global businesses include partnerships, new product launch, acquisitions.


The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report - 

Would like to place an order or any question, please feel free to contact at